ArticleDigestive diseases and sciences2026
Association of Circulating Protein Biomarkers of Gut Barrier Integrity and Inflammation with Colorectal Adenomas and Colorectal Cancers.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLoss of gut barrier integrity, bacterial translocation and related inflammation are emerging etiological links in the development and progression of colorectal cancer (CRC).
aimThis study investigated associations between circulating biomarkers of gut barrier functionality and inflammation with colorectal adenoma (CRA, n = 49), CRC (n = 108), and controls (n = 101) in case-control studies from Ireland and the Czech Republic.
methodsCirculating concentrations of the biomarkers were measured using enzyme-linked immunosorbent assay (ELISA), and Mesoscale Discovery immunoassays. Multivariable logistic regression was used to generate odds ratios (ORs) and 95% confidence intervals (CIs), analysing the associations between the biomarkers and disease stages. Diagnostic performance was assessed through receiver operating characteristic (ROC) curves and area under the curve (AUC) analysis.
resultsHigher calprotectin concentrations were positively associated with CRC in both Irish and Czech cohorts and in the combined meta-analysis (OR = 1.81, 95% CI: 1.10-2.96; OR = 1.98, 95% CI: 1.27-3.11; OR = 1.16, 95% CI: 1.00-1.35, respectively). IL-8 was positively associated with CRC in the Czech cohort and the meta-analysis (OR = 2.43, 95% CI: 1.32-4.48 and OR = 1.92, 95% CI: 1.29-2.86, respectively). The optimal diagnostic biomarker combination in the meta-analysis included calprotectin, IL-8, lipopolysaccharide binding protein (LBP), and C-reactive protein (CRP), achieving an AUC of 0.70 (95% CI: 0.61-0.79).
conclusionOur results suggest that a dysfunctional gut barrier may contribute to development and progression of colorectal neoplasia, while combinations of proteins involved in gut integrity may serve as diagnostic biomarkers.
Indexed as
Identifiers
41379292What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.